Drugs / EnVAX-A71
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05099029 | Jun 2018 → Aug 2024 overdue | enterovirus infectious disease | Enimmune Corporation | Active not recruiting | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EnVAX-A71 | “We evaluated EnVAX-A71, a bioreactor-produced, aluminum-adjuvanted inactivated EV-A71 (B4/E59) vaccine, in a randomized, double-blind, placebo-controlled phase 3 trial in...” PMID 41680199 ↗ Feb 2026 |
| Modality | Vaccine | “EnVAX-A71, a bioreactor-produced, aluminum-adjuvanted inactivated EV-A71 (B4/E59) vaccine” PMID 41680199 ↗ Feb 2026 |